Cytosorbents Corp (CTSO) 2019 Q4 法說會逐字稿

Good afternoon, and welcome to the CytoSorbents 2019 Financial and Operating Results Conference call. (Operator Instructions) Please be advised that the call will be recorded at the company's request.

At this time, I'd like to turn the call over to our moderator, Jeremy Feffer. Please go ahead, Mr. Feffer.

Thank you, Omar, and good afternoon. Welcome to CytoSorbents 2019 Financial and Operating Results Conference Call. Joining me today from the company are Dr. Phillip Chan, Chief Executive Officer and President; Vincent Capponi, Chief Operating Officer; Kathleen Bloch, Chief Financial Officer; Dr. Christian Steiner, Senior Vice President of Sales and Marketing from Germany; and Chris Cramer, Vice President of Business Development.

Before I turn the call over to Dr. Chan, I'd like to remind listeners that during the call, management's prepared remarks may contain forward-looking statements, which are subject to risks and uncertainties. Management may make additional forward-looking statements in response to your questions today. Therefore, the company claims protection under safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Actual results may differ from results discussed today, and therefore, we refer you to a more detailed discussion of these risks and uncertainties in the company's filings with the SEC. Any projections as to the company's future performance represented by management include estimates as of today, March 5, 2020, and we assume no obligation to update these projections in the future as market conditions change.

During today's call, we will have an overview presentation covering the operating and financial highlights for 2019 by Dr. Chan and Ms. Bloch. Following that presentation, we will open the line to your questions during the live Q&A session with the rest of the management team.

At this time, it's my pleasure to turn the call over to Dr. Phillip Chan. Phil?

Thank you very much, Jeremy, and good afternoon, everyone.

In 2019, we made good progress. We delivered 80,000 plus CytoSorb cumulative treatments, up from 56,000 a year ago. 2019 total revenue was $24.9 million, including product sales and grant income versus $22.5 million a year ago. Product sales growth accelerated in the fourth quarter of 2019 by 20% driven by a 30% increase in direct sales. And we achieved our guidance of blended product gross margins of 80% in the fourth quarter of 2019. An important milestone was the renewal of our CytoSorb CE Mark to May 2024 and our ISO 13485:2016 manufacturing certification to September 2022. We also expanded our organization throughout the year in 2019 by 50% to approximately 155 employees, with a strong focus on commercialization. We also extended CytoSorb distribution to a total of 58 countries, including 10 countries where we sell direct with our own sales force. And we are now well capitalized with cash to fund operations and clinical studies through the second half of 2021.

Dominating the headlines is the COVID-19 pandemic. Allow me to summarize our progress. First, CytoSorb is in many of the countries where COVID-19 cases are surging, including Italy, Iran, Germany, France, Spain, Hong Kong and others. And through our new partnership with China Medical System Holding Ltd, a publicly traded specialty pharma company based out of China with more than USD 800 million in sales annually, we donated initial CytoSorb devices that were made rapidly available to select hospitals in Wuhan, China. We have learned now that multiple patients at multiple hospitals are being actively treated with CytoSorb. While the data are not yet available on clinical outcomes, they are expected to be made available in the near future. As part of this process, physicians from Peking Union Medical College Hospital, one of the most prestigious hospitals throughout all of China, who have been treating patients in Wuhan hospitals, recently registered a trial entitled, CytoSorb adsorption therapy combined with standard therapy for new coronavirus pneumonia in adult severe patients, in order to have a mechanism to collect and publish ongoing safety and efficacy data from patients that they are currently treating.

On March 3, 2020, just days ago, the National Health Commission in China issued its seventh updated treatment guidance called Diagnosis and Treatment of new Coronavirus Pneumonia, that now includes the recommendation to use blood purification to treat cytokine storm for severe and critically ill patients who have coronavirus infection. We have also submitted our documentation to the U.S. joint agency task force that includes the CDC, HHS, the FDA as well as BARDA and others that are -- and others and are awaiting feedback. And we're currently manufacturing CytoSorb and ramping manufacturing of CytoSorb to build inventory of devices should there be a need. Given the 3-year shelf life of our products, this increase in inventory can be easily worked through with low risk based upon our underlying existing business.

Some observations. One, we contend that COVID-19 would not be so concerning if therapies were available to lower the high 2% to 4% mortality rate. Currently, most of the cases of coronavirus are relatively mild. But this is exactly what CytoSorb has intended to do. Secondly, investors should realize that all of the reasons that make our therapy applicable to the treatment of the complications of coronavirus are what CytoSorb treats every single day around the world. The problem with cytokine storm and organ failure is not unique to COVID-19. In fact, it is very common in life-threatening illnesses, such as sepsis, burn injury, trauma, liver failure, complications of cardiac surgery and other surgeries and cytokine release syndrome and many other illnesses. Sepsis, our core market, accounts for 1 in every 5 deaths worldwide each year. Coronavirus may be the reason why investors buy our stock now, but what we do every day, year in and year out, is why they should stay.

And now let me turn to a clinical update. So a quick update on our REFRESH 2-AKI trial and our CMO search. We are working closely with our new CRO to close out remonitoring and scrubbing of clinical data on the first 153 patients in the REFRESH 2-AKI trial, all of which remains usable data. We do not have to enroll an additional 153 patients to cover for these patients. All of this data is usable. We also expect to address the data and data analytical request of the data monitoring committee, the goal of restarting review by mid-2020. Provided we are able to regain momentum of our trial, our goal is to get to the scheduled interim analysis with 200 patients enrolled by the end of 2020 or the first quarter of 2021. In terms of our Chief Medical Officer search, we are actively conducting a routine search for a new Chief Medical Officer and have several highly qualified candidates with more under evaluation. We expect to conclude the search no later than the next few months.

A quick update on the U.K. TISORB study and our U.S. strategy for ticagrelor removal. The U.K. TISORB study now has 6 of 8 centers active with 1 patient enrolled. Part of the delay was a protocol amendment that was submitted to enable enrollment of not just emergent patients but also urgent cardiac surgery patients, which was approved by the U.K. Medicines and Healthcare products Regulatory Agency, or MHRA, at the end of February. We're now currently waiting on regional ethics committees to approve this new protocol. And we expect to enroll the 30 patients in the study by the second half of 2020.

In terms of our U.S. strategy, we are in active discussions with the FDA on a path forward for the removal of ticagrelor during cardiac surgery, and we expect to have clear feedback from the FDA no later than the first half of this year.

Now an update on REMOVE. As you recall, REMOVE is the infective endocarditis trial that is being funded by the German government. And I'm pleased to say that the REMOVE endocarditis trial has completed enrollment at 288 patients in January. Currently, the data is being monitored with the goal of database lock soon. Data analysis on outcomes are expected in mid-2020. I would also note and point to a recent press release on the publication of a single center, 58-patient infective endocarditis retrospective case series from the University of Essen that is separate from the REMOVE trial. But what they demonstrated was a statistically improved hemodynamic stability upon ICU admission following surgery as well as a lowered incidence of postoperative sepsis and death related to sepsis, all of which is encouraging ahead of top line data from the REMOVE trial.

And last but not least, on HemoDefend. The manufacturing issue that we had disclosed previously has now been resolved, and we're now in validation testing to confirm this. Manufacturing new devices will follow very shortly. And we expect to complete bench testing on new devices for efficacy parameters by mid-2020. The IDE application for U.S. pivotal -- for the U.S. pivotal trial is expected to be filed and approved, hopefully, by the end of 2020, with the trial to occur shortly thereafter.

So with that, allow me to pass this on to Kathy for the financial highlights. Kathy?

Thank you, Phil, and good afternoon, everyone. For today's call, I'll provide an update regarding CytoSorbents fourth quarter and full year 2019 now audited financial results. And in addition, I'll provide an update around our working capital and cash runway.

CytoSorb product sales for the fourth quarter of 2019 were approximately $6.6 million, which represents a 21% increase over product sales of approximately $5.4 million for the fourth quarter of 2018. This is a new company record for quarterly product sales. This increase in sales was driven by an increase in direct sales from both new customers and repeat orders from existing customers. The decline in the average euro to dollar exchange rate had a negative impact of $161,000 on the fourth quarter 2019 sales. Our total revenues, which include product sales and grant revenue, were approximately $7.4 million in the fourth quarter of 2019 compared to approximately $6.1 million for the fourth quarter of 2018, an increase of approximately 22%. Our fourth quarter gross profit grew to approximately $5.3 million, which is an increase of 33% or roughly $1.3 million over gross profit of approximately $4 million for the fourth quarter of 2018. And as Phil mentioned, our gross profit margins on product sales were 80% for the fourth quarter of 2019. This is a very important milestone for the company, and this is as compared to 75% for the fourth quarter of 2018. Primarily, this is due to production efficiencies that were achieved by the company.

Turning to our annual results for 2019. Product sales were approximately $22.8 million, a 12% increase over product sales of approximately $20.3 million for 2018. This increase was primarily driven by an increase in direct sales of approximately $3.2 million, and we saw this particularly in Germany. Distributor sales fell by approximately $681,000 as a result of the pause in orders from 3 distributors, an issue which we believe is now behind us. On a constant currency basis, 2019 product sales would have been approximately $24 million, which is an increase of 18% over 2018 product sales. 2019 grant revenue was $2.2 million, which is just slightly below 2018 grant revenue. And our total revenues, which include product sales and grant revenue, were approximately $24.9 million for 2019 as compared to $22.5 million for 2018, an increase of approximately 11%. 2019 gross profit was approximately $17.6 million, which is an increase of $3.6 million or 17% over gross profit in 2018.

So we'll look at our chart of quarter-over-quarter product sales, and we see that our product sales of $6.6 million were a new record in quarterly product sales. And we are especially seeing strength in our direct sales, which rose 30% in the fourth quarter of 2019 as compared to the fourth quarter of 2018. And with the investments we made in the second half of 2019 in the direct sales team and in our sales and marketing infrastructure, we expect the ROI on this investment to accelerate our sales growth given additional time.

And now we'll look at our chart of year-over-year product sales. Our year-over-year product sales continue to grow. Again, constant currency sales for 2019 would have been $24 million, which is an increase of 18% over 2018 product sales. And also, we're showing on this chart a solid line, which represents our product gross margins. And as you can see, they have also continued to improve over the years, now at 80% in the fourth quarter of 2019. As we move into 2020, we do anticipate other production efficiencies will be achieved, and they will further improve our product gross margins.

In the fourth quarter of 2019, excluding clinical trial costs, we were approximately $1 million away from cash operating breakeven. With continuing restraint with regard to our operating spend, future sales growth and continuing improvements in our product gross margins, we expect to reach quarterly cash operating breakeven, as defined, before the end of 2020.

And now we'll take a look at our working capital and cash position. As of December 31, 2019, we had approximately $12.2 million in cash. We have additionally disclosed today in our Form 10-K that from January 1 through March 2, 2020, we've generated approximately an additional $13.3 million in cash by utilizing our ATM, at the market, equity facility. And we believe that this additional cash solidifies our cash position for the future and provides a cash runway to support our operations and clinical trial strategy into, at a minimum, mid-2021.

So during 2020, we sold approximately 2.4 million shares at an average price of $5.64 per share. And we do believe that the ATM provides an efficient and very cost-effective way for us to raise funds for the company. I think it's also important to note that historically, we have only utilized the ATM when our stock price is strengthening.

Turning to our capital structure. As of December 31, 2019, we've approximately 37 million common shares outstanding on a fully diluted basis. And that concludes my remarks. And at this time, I'd like to turn the call back to Phil.

Thank you very much, Kathy. And in terms of guidance, CytoSorbents has not historically given specific financial guidance on quarterly results until the quarter has been completed. However, we expect that first quarter 2020 product sales will exceed first quarter 2019 product sales driven by strength in our direct sales force as well as international sales.

That concludes our current prepared remarks. I would like to now open it up for a live Q&A session. Moderator?

(Operator Instructions) We will take our first question today from Andrew D'Silva, B. Riley and FBR Company.

Sorry if you did touch on this. I did have to hop between a couple of calls. But just a couple of quick ones. First off, just as it relates to Fresenius and then Mexico and South Korea, can you talk about what needs to be finalized and what the cadence looks like in orders with the remaining EU inventory? And then potential reorders. Is there a sense of what the timing could look like there? I'm just curious on how meaningful we should expect that to be.

Yes. I think that Fresenius has done a nice job in Europe in working down their inventory, and we expect them to actually be in a position to potentially order this quarter. They continue to have France, Finland and the Czech Republic and have been doing well in those countries.

In terms of Mexico and South Korea, what we've stated in the past is that Mexico should be coming online soon, followed by South Korea. The current COVID-19 outbreak in South Korea may be a facilitator to driving earlier registration in South Korea, but that remains to be seen. But hopefully, you should be hearing about Mexico sometime soon.

You're the first company during this earning season that I had that actually said that would accelerate something for them in an adoption standpoint. And then as far as the label expansion with Brilinta. I'm just curious, obviously, it's been capturing market share from Plavix. But still, Plavix will have a dominant market share. Is there a potential utilization for CytoSorb with other antiplatelets? Or is the ability to not permanently bind make Plavix a nonstarter?

Yes, it's a very good question. So interestingly, Plavix -- and so the 3 antiplatelet agents today that are common are clopidogrel, or Plavix; ticagrelor or Brilinta; and prasugrel, also called Effient. It turns out that clopidogrel and prasugrel are irreversible inhibitors of platelet function and covalently bind to the P2Y12 receptor and technically are not reversible. Ticagrelor, technically, is the only reversible P2Y12 platelet inhibitor. However, because of the lack of any approved reversal agents, they have never been able to capitalize on that reversibility claim. As you can imagine, that's a very important feature because in patients who require emergency surgery or have a sudden GI bleed or involved in a motor vehicle accident are bleeding, it would be very helpful to be able to reverse ticagrelor. But I think that's what CytoSorb brings to the table. CytoSorb actually now can reverse the effects of ticagrelor when used to remove it during emergency cardiac surgery when placed into a cardiopulmonary bypass side circuit during open heart surgery. And this was again demonstrated in an observational study that was published last year from St. Georg Asklepios Hospital in Hamburg, Germany.

What we believe is that this has the potential to change the current prescribing patterns for these antiplatelet agents. Today in patients who, in the United States and elsewhere, who present to the hospital with acute coronary syndrome, they are typically loaded up on an antiplatelet agent. And today, Plavix, or clopidogrel, is typically prescribed much more frequently than the other 2 because it's very inexpensive even though it does not work as well, and is shown to be inferior in multiple studies, but it is used because it's inexpensive. Ticagrelor has been -- is typically, in terms of patients with myocardial infarction, is currently about 1/3 of the market in terms of market share. However, we believe that by having -- so today, interventional cardiologists are loading patients with acute coronary syndrome on these antiplatelet agents with the understanding that roughly 10% of patients that undergo percutaneous coronary intervention and stent placement will not be candidates for a stent placement and will require open heart surgery or a coronary bypass graft, or CABG, surgery to fix their underlying problems because of things like left vein disease or multi-vessel disease or intractable ischemia or cardiogenic shock or other reasons to require CABG. Also included in there is any kind of complications of PCI, such as dissection of the coronary artery.

Today, they're loaded indiscriminately on these antiplatelet agents. But we think that going forward, now that interventional cardiologists know that there is a reversal agent for one of the antiplatelet agents, it could be used during open heart surgery to prevent unwanted and potentially fatal bleeding postoperatively in CABG -- emergency CABG patients that there will be a tendency to prescribe ticagrelor and load patients up on ticagrelor over time. And given that ticagrelor will also go off patent, it's believed by 2024, the cost differential between ticagrelor and clopidogrel should also decrease significantly. Because of that, the use -- the ability to be used with ticagrelor is a major advantage for us, and that there is currently not a need to reverse Plavix and prasugrel. Hopefully, that makes sense.

No, no. Perfect sense. Great color there. I could ask a thousand questions. I'll just ask one more. Does that mean as far as when you're looking at the macro landscape, you got Portola Pharma and they have their antidote for rivaxavan (sic) [rivaroxaban], I think is the generic name for -- and then there's been progress being made with PhaseBio and Brilinta. How do you think about the drugs being utilized as a reversal agent versus a device? And when we start thinking about the co-marketing potential with drug and pharma companies, is that something we should expect as a potential driver down the road?

So first of all, has been demonstrated to be able to remove not just ticagrelor, which is one of the P2Y12 platelet inhibitors, but has also been demonstrated to be able to promote rivaroxaban and apixaban, rivaroxaban or Xarelto that has currently about $6 billion in worldwide sales. And then also, apixaban, which is also called Eliquis, which has about $10 billion in worldwide sales. Apixaban and rivaroxaban are in a class of antithrombotics called factor Xa inhibitors. So currently, the only factor Xa inhibitor reversal agent on the market is Portola's Andexxa. And we are -- based upon the data that they presented, there are reasons why our therapy would be a better reversal agent for cardiac surgery patients given that the reversal agent only is effective during the time of infusion. It also has a black box warning of being prothrombotic, which is a negative in patients undergoing cardiac surgery, and also is a very expensive drug.

In terms of PhaseBio, this is a product that is technically a reversal agent for ticagrelor. It is currently in a Phase IIb study right now with the goal of getting to a Phase III study soon, meaning this quarter or next quarter. But again, it's a biologic that is that -- well, I think at the end of the day, be not very cost-competitive with our product given that it is a biologic and that it will expire while on the shelf and will have to be repurchased at high cost by the hospital. And so we'll see how the dynamics work out. But for cardiac surgery, we believe that our product, which is easily installed into the cardiopulmonary bypass machine and has a relatively reasonable and cost-effective cost, as we've demonstrated in a study that came out last year showing that even taking into consideration the cost of the device, that use of the device per patient would save hospitals a projected $5,000. We believe that CytoSorb would actually be a very easy therapy to be able to use for this application in cardiac surgery patients. And so we'll see how that turns out.

So that being said, we currently have expanded the label for CytoSorb to include now ticagrelor removal during cardiopulmonary bypass and cardiac surgery. This is now applicable to all the countries where CytoSorb is currently being distributed, so all 58 countries. And we are also working to expand that to other antithrombotic agents as well. We are also working on using this as a springboard for potential U.S. regulatory path. And again, as I mentioned in my comments, we'll have more detail on that, hopefully soon.

I get the last part of that question, which is related to partnering with pharma. AstraZeneca, for example, at least while PhaseBio is still in clinical trials, actually, they have some sort of a connection together there from a partnership standpoint. But in the interim, I mean, they have a small window left to be able to really capitalize before generics start coming into the market. Just from our understanding, make a lot of sense for them to work with you to help with their adoption.

Well, I think that the goal of a lot of pharmaceutical manufacturers is to maximize the revenue opportunity for their drugs, particularly the ones that are very key to their pipeline. And so the ability to dominate a market or the potential to dominate market should be very attractive and to be able to eliminate the competitors from that market. So that's all I can say at this time.

Our next question is from Josh Jennings, Cowen.

This is Eric on for Josh. Just looking at CytoSorb's use in China, do you intend to report the outcomes associated with COVID-19 treatment in China on a case-by-case basis? We're just trying to think of how many cases could be reported when it's announced.

I think that the goal here is to create a sufficient number of patients to be able to make some type of assessment of the efficacy of the therapy in those patients. I think what we've seen is that multiple patients are being treated at multiple hospitals. And so I think that's very helpful in terms of achieving that goal. There is a very strong interest in anything to do with coronavirus as a publication given how it's now spreading to all corners of this globe. And China, having the most experience with this, is -- scientists there are and researchers there are very motivated to get those studies published. So our hope is that whatever comes of this evaluation, that those data are made available in a very timely fashion.

And then what's the earliest do you think we could see a U.S. trial for ticagrelor removal? Is it possible for you to outline generally what you think that could look like in terms of the number of patients, endpoints or just anything with time lines for that study? That would be great.

In terms of time line, we'll have, again, a better sense of regulatory path in the first half of this year, we believe. If you look at some of the other reversal agents that are in clinical studies, there's been a precedent set for certain endpoints involving, for example, a reversal of platelet inhibition or a reversal of the specific effects of the drug. So we'll see what that looks like. But once we have some better clarity on the path, we will definitely let you know.

Our next question is from Sean Lee, H.C. Wainwright.

Congratulations on a great quarter. My first question is on the COVID-19 uses. You mentioned that you've partnered in China to use CytoSorb, and you've also submitted documents to the joint task force in the U.S. But are you working with any of the other governments, perhaps in Europe, on this?

We are looking to get treatment experience with hospitals in these various countries where we already have relationships so it is not necessary. We are already approved, as you're aware in the European Union and other countries where these cases are surging. And with the exception of South Korea, where we're pending registration. But that being said, there's not a need necessarily to work with the government per se. The goal is to work with intensiveness to basically drive treatment experience data.

I see. Thanks for the clarification on that. And second, for the gross margins, you hit a high of 80% and this year -- last year. So I was wondering whether we can see further improvements this year and where do you see can get to in the next 2 to 3 years.

Let me turn that over to Vince. Vince, could you comment on that, please?

Sure. Thanks, Phil. Sean, regarding the gross margins, we still have upside on the gross margins as we increased volume and then increase -- our product mix obviously plays a role in that. But we also have another -- a number of cost-downs that we're working on to continue to improve the efficiency. So we still see upside. But really, Sean, it will be somewhat dependent upon what the volumes are in production as well as what the product mix. So it would be difficult at this point to exactly project where we would be 2 or 3 years from now, but it should be definitely north of where we are if we maintain this volume and increase this volume from where we are today.

That's great to hear. My last question is on HemoDefend. You mentioned that the manufacturing issue has been resolved, and you expect to file for IND -- I'm sorry,IDE close to the end of this year. I was wondering what's the pivotal study is expected to look like. And would that be conducted under a partner contract? Or would that be independently funded?

Yes. So yes, so the HemoDefend pivotal study is a relatively straightforward trial, approximately 25 healthy volunteers receiving blood that's been treated by our HemoDefend blood filter. And it really is a cell longevity assay, making sure that our device is not doing anything untoward to the packed red blood cells that would reduce their longevity in circulation. So it's a very straightforward study that is commonly done for other products all the time.

And so in terms of funding, we have been awarded a grant from National Heart, Lung and Blood Institute, a division of NIH that has funded this program to the tune of approximately $5 million, part of which was funded by also the Special Ops Command, or SOCOM, U.S. SOCOM. But that being said, the current phase that we're in is a 50-50 split on expenses. And we believe that the study, the additional testing that needs to be done as well as the study itself, will be subsidized by 50% by this grant by National Heart, Lung and Blood Institute.

(Operator Instructions) Our next question is from Jeb Terry, Aberdeen Asset Management.

Phil, can you hear me?

Yes, yes, I can.

Okay. Great. 3 questions. One, on the China guidelines, is there some other way for a Chinese hospital to comply with those guidelines other than CytoSorb?

Blood purification is common, as we've disclosed in our 10-K. There are a couple of companies trying to do what we do. And again, not wanting to get into too much detail, we believe that we have the superior technology that has the most clinical data in any type of clinical applications related to the complications of coronavirus or complications of sepsis or complications of a wide variety of factors in critical care. For that reason, we believe that we are the leading therapy -- blood purification therapy in critical care today.

So presumably then those guidelines actually can't be -- there's no right way to put this, and there's no compliance, if you will, with those guidelines as it stands in China?

No, they're not mandatory guidelines. These are guidelines that are, of course, voluntary, but they're making suggestions based upon available data and also mechanism of action and other factors.

Right. Well, I guess then, it sounds like there isn't someone else who's already doing what you do there. This is kind of prospective. China would like you to see to this. So -- okay. Then the second thing is relative to your building of inventory, can you refresh my memory on what your capacity is? So if things really took off in China and elsewhere, what would be your ability to meet that demand?

Vince, would you like to take that question?

Sure. Jeb, so we've always stated our capacity to be enough to support an $80 million business. We never come out specifically with units. Again, we have -- the second part of the plant we just started up recently that we've talked about previously, the second part of the upgrade, if you will. And so that capacity is now online. So we have a fair amount of capacity that we could utilize today to be able to address needs in China and rest of world, for that matter. But it would be up to an $80 million business roughly based on current pushout.

That's right. I look forward to you being challenged on that capacity.

Yes, it's a good problem to have. I agree.

That would be a great problem. And so with respect to the fact that you are quite active in European hospitals, Italy, for example. And Italy is having these issues. Are there patients or hospitals in Italy now utilizing, since they're familiar with your product, are they, in fact, treating patients at this point?

So we know that many hospitals throughout Italy use our product for every day critical illness, such as sepsis and other things. We have not heard any feedback yet about whether or not hospitals are using the product yet. But what we find is that for particularly new applications, there's often a delay before we hear what has been going on. So we actively are working with our distributor, Aferetica, to try to get at that information. But again, I think that when information comes out if there are successful treatments using our therapy, it is something that we would certainly like to get out.

And then one last thing, if I might. You said that you've been in discussions with -- in the U.S. with the task force for treating coronavirus. Can you give us a sense of what that's like, what the time line or process might be or what's entailed in that?

What we've said is that we've had preliminary discussions with BARDA on this application and we have submitted our materials, as have many other companies that are trying to develop either therapies or diagnostics for this space. I think that we are very unique in our approach, particularly in the United States. And one of the few companies that are actually -- actually have a product that is being used for those applications, unlike many companies that have a theoretical application. So although to be clear, we have not, aside from the patients that we know about, our goal is to really -- our goal is not to treat necessarily the virus itself, but to treat complications of the virus infection, which are things like respiratory failure, shock, organ failure and other things.

Our next question is from Jason Kolbert, Dawson James.

Congratulations on a great quarter. Certainly very exciting to see kind of the use and data and the application of lifesaving technology in China. And I'm sorry, I came to the call late. So if you answered this, I apologize. But I am hearing about a tremendous infection rate in Japan, even though you don't see the numbers reported. And I am -- I just got off the phone with some people in Israel. And I know that both Japan and Israel are very focused on having treatments and therapies. So I just wonder, beyond the borders of the U.S. and China, where else you might be in discussions to make CytoSorb available?

Well, again, in Japan, I think there's a very strong interest in trying to control the spread, particularly with the Olympics coming up there soon. And so I think that we are actively working on a strategy to get into the Japanese market. As you know, one of our partners is Terumo Cardiovascular, which is a Japanese conglomerate.

In terms of Israel, we are already registered in Israel and are available in Israel through our distributor, Gad Medical. And if they so desire to use our product, it is currently available there.

Okay. I really appreciate the refresher because, I mean, those are critical details right now. And I do think you will see the rates in Japan just jump higher when they begin testing people.

At this time, I would like to turn it back to management for any additional or closing remarks.

Well, thank you, everyone, for participating in today's call. If you have any additional questions, please reach out to Jeremy Feffer at jeremy@lifesciadvisors.com, and we'll try to reply to your questions where possible. Thank you very much, everyone. Have a good night.

Thank you. That concludes our conference for today. I would like to thank everyone for their participation. Have a great evening.